Ann: Imugene to Present HER-Vaxx Phase 2 Data at AACR21 Meeting, page-104

Hi Davy,

Wow you are famous on HC today lol! And you thought your post was tedious or boring? See it wasn’t mate .

That is interesting in reference to Ph1b/Ph2 & the contents of this abstract. This trial basically morphed into the Ph2, so it’s a little different to a seperate Ph1-Ph2 scenario.

Abstracts are often required to be submitted many months in advance before a conference for consideration for inclusion, so it would be interesting to look at the cut off date for this.

The abstract is opened-ended as the trial is ongoing citing the link to clinical trials.gov & interesting it doesn’t contain most recent data. So it’s very possible we will see some new stuff in the poster once the embargo is lifted.

Note: you cannot just re-present data that previously has been published or presented elsewhere, without building on that with new original data. When publishing or presenting you have to sign a document to that effect & also that it’s your own work, plus any disclosures (ie sponsorship) or conflicts of interest.

Have a beautiful weekend all & congrats on a great close today.